WO2000040253A1 - Molecules synthetiques hautement chargees et utilisations de celles-ci - Google Patents

Molecules synthetiques hautement chargees et utilisations de celles-ci Download PDF

Info

Publication number
WO2000040253A1
WO2000040253A1 PCT/US2000/000338 US0000338W WO0040253A1 WO 2000040253 A1 WO2000040253 A1 WO 2000040253A1 US 0000338 W US0000338 W US 0000338W WO 0040253 A1 WO0040253 A1 WO 0040253A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
tumor
cell
pharmaceutical compound
heparin
Prior art date
Application number
PCT/US2000/000338
Other languages
English (en)
Inventor
Ralph D. Sanderson
Carla Y. Pumphrey
Original Assignee
The Board Of Trustees Of The University Of Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The University Of Arkansas filed Critical The Board Of Trustees Of The University Of Arkansas
Priority to AU26022/00A priority Critical patent/AU2602200A/en
Publication of WO2000040253A1 publication Critical patent/WO2000040253A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Definitions

  • Neoproteogylcans nPGs
  • neoproteoglycans As controls, purified syndecan-1 ectodomain was added at 1 nM, a concentration known t o inhibit cell growth by more than 75%. Negative controls included pretreatment of neoproteoglycans with heparinase or chondroitinase which should abolish growth inhibitory effects. Assays were performed on cells growing in 96 well plates and cell numbers present after 4 days were assessed spectrophotometrically a s described (Mali, et al., 1994). Neoproteoglycan reduced myeloma cell viability ( Figure 1). Apoptosis was analyzed using antibody t o Apo 2.7 (Coulter), a mitochondrial protein expressed early in committed apoptosis pathways.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une molécule synthétique composée d'une unité chargée liée de manière covalente à un groupe fonctionnel, et un procédé de confection de celle-ci. Plus particulièrement, une chaîne glycosaminoglycane est liée de manière covalente à un groupe fonctionnel de façon à synthétiser un protéoglycane. Parmi les exemples de groupes fonctionnels on compte l'albumine sérique humaine, β2 microglobuline, avidine, un peptide et un lipide. Cette invention concerne aussi diverses applications thérapeutiques de ces molécules synthétiques.
PCT/US2000/000338 1999-01-08 2000-01-07 Molecules synthetiques hautement chargees et utilisations de celles-ci WO2000040253A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU26022/00A AU2602200A (en) 1999-01-08 2000-01-07 Synthetic, highly charged molecules and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11505399P 1999-01-08 1999-01-08
US60/115,053 1999-01-08

Publications (1)

Publication Number Publication Date
WO2000040253A1 true WO2000040253A1 (fr) 2000-07-13

Family

ID=22359039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/000338 WO2000040253A1 (fr) 1999-01-08 2000-01-07 Molecules synthetiques hautement chargees et utilisations de celles-ci

Country Status (2)

Country Link
AU (1) AU2602200A (fr)
WO (1) WO2000040253A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007004975A1 (fr) * 2005-07-01 2007-01-11 Corline Systems Ab Revêtement d’héparine sur un tissu biologique
WO2008041930A1 (fr) * 2006-10-06 2008-04-10 Corline Systems Ab Ensemble moléculaire sur un substrat
US8106007B2 (en) 2005-02-01 2012-01-31 N.V. Organon Conjugates of a polypeptide and a pentasaccharide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466966A1 (fr) * 1989-01-20 1992-01-22 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Sulfate de chondroitine protéoglycane synthétique et procédé pour sa préparation
US5464942A (en) * 1990-07-24 1995-11-07 Seikagaku Kogyo Kabushiki Kaisha Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same
WO1995034316A1 (fr) * 1994-06-13 1995-12-21 Jalkanen Markku Tapani Suppression de la croissance des cellules tumorales a l'aide de l'ectodomaine du syndecane-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466966A1 (fr) * 1989-01-20 1992-01-22 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Sulfate de chondroitine protéoglycane synthétique et procédé pour sa préparation
US5464942A (en) * 1990-07-24 1995-11-07 Seikagaku Kogyo Kabushiki Kaisha Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same
WO1995034316A1 (fr) * 1994-06-13 1995-12-21 Jalkanen Markku Tapani Suppression de la croissance des cellules tumorales a l'aide de l'ectodomaine du syndecane-1

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DHODAPKAR ET AL.: "Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.", BLOOD, vol. 91, no. 8, 15 April 1998 (1998-04-15), pages 2679 - 2688, XP002927344 *
GONZALEZ ET AL.: "OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel Overgrowth Syndrome, induces apoptosis in a cell-line specific manner.", J. CELL BIOL., vol. 141, no. 6, 15 June 1998 (1998-06-15), pages 1407 - 1414, XP002927346 *
INKI ET AL.: "The role of syndecan-1 in malignancies.", ANN. MED., vol. 28, no. 1, February 1996 (1996-02-01), pages 63 - 67, XP002927348 *
KARASAWA ET AL.: "Inhibition of experimental metastasis and cell adhesion of murine melanoma cellsby chondroitin sulfatederivatized lipid, a neoproteoglycan with anti-cell adhesion activity.", CLIN. EXP. METASTASIS, vol. 15, no. 2, 1997, pages 83 - 93, XP002927345 *
KUBERAN ET AL.: "Preparation and isolation of neoglycoconjugates using biotin-streptavidin complexes.", GLYCONJUGATE JOURNAL, vol. 16, June 1999 (1999-06-01), pages 271 - 281, XP002927347 *
MALI ET AL.: "Suppression of tumor cell growth by syndecan-1 ectodomain", J. BIOL. CHEM., vol. 269, no. 45, 11 November 1994 (1994-11-11), pages 27795 - 27798, XP002927343 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106007B2 (en) 2005-02-01 2012-01-31 N.V. Organon Conjugates of a polypeptide and a pentasaccharide
WO2007004975A1 (fr) * 2005-07-01 2007-01-11 Corline Systems Ab Revêtement d’héparine sur un tissu biologique
US8153147B2 (en) 2005-07-01 2012-04-10 Corline Systems Ab Heparin coating of biological tissue
WO2008041930A1 (fr) * 2006-10-06 2008-04-10 Corline Systems Ab Ensemble moléculaire sur un substrat
US8323986B2 (en) 2006-10-06 2012-12-04 Corline Systems Ab Molecular assembly on a substrate

Also Published As

Publication number Publication date
AU2602200A (en) 2000-07-24

Similar Documents

Publication Publication Date Title
CA2213198C (fr) Therapie genique par agents anti-tgf-.beta.
Misra et al. Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer
Isaka et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney
Platt et al. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor
US10583084B2 (en) Liposomal formulations for delivery of nucleic acids
Kakkar et al. Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma
CA2248549A1 (fr) Molecules de signalisation de matrice extracellulaire
JPH11500108A (ja) 親水性分子の脂質化のための方法および組成物
KR20050054907A (ko) 조직 손상의 치료 및/또는 조직 회복의 촉진에서ｈｍｇｂ1 단백질의 용도
JP2003528131A (ja) カチオン性リポソーム
CZ137597A3 (cs) Konjugáty BDNF a NT-3 s vodou rozpustným polymerem
EA010055B1 (ru) ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
JPH08503605A (ja) 細胞に導入された遺伝子の発現を増大し及び／又は延長する方法
CN110760008A (zh) 低pH插入肽的融合蛋白、药物组合物及应用
JP2001511784A (ja) 改変された腫瘍壊死因子
JP2002502831A (ja) 癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与
JP2022531010A (ja) 薬物送達キャリア及びそれを用いた医薬製剤
JP2002502243A (ja) トランスフェクション活性を有するインテグリン−ターゲッティングベクター
JP2013234202A (ja) 過活動膀胱障害の治療のためのスフィンゴミエリンリポソーム
CA3146530A1 (fr) Application d'un polypeptide ou d'un derive de dernier
WO2006082763A1 (fr) Procede permettant de regenerer une fibre elastique en utilisant dance ou un facteur renforcant son expression
WO2000040253A1 (fr) Molecules synthetiques hautement chargees et utilisations de celles-ci
JP3903503B2 (ja) 可溶性ポリペプチド
CN1788017B (zh) 炎症状态下在血脑屏障中差异表达的核酸
JPH07505161A (ja) 新規な枝角−由来の骨成長因子

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase